EFIRM is peer-reviewed and credentialed.
EFIRM stands for electric field induced release and measurement. EFIRM is EZLife Bio’s core technology that detects the presence of DNA or other biomolecules. The steps involving EFIRM assay are:
The EFIRM platform is actuated by an electrochemical control system that works in 96-parallel channels. This electrochemical control system connects to a gold electrode array with the footprint of a traditional microtiter plate.
EFIRM is actuated molecularly by coating the gold electrodes with a highly efficient conducting polymer method that allows for the rapid immobilization of DNA probes, antibodies, antigens, and other small molecules. These biomolecules are immobilized in such high amounts that they form a highly sensitive molecular capture layer. This conducting polymer layer is then combined with a pulsed electric field method and enzymatic electrochemical readout system, which an instrument reads at the nanoamp-scale, allowing for highly sensitive measurement of biomolecule levels.
EFIRM as a liquid biopsy tool has been validated in numerous blinded clinical tests in the United States, Taiwan, and China. In these results, there was a >95% concordance between EFIRM liquid biopsy (saliva,plasma) and genotyping results from tissue based genotyping using traditional extraction and quantitative PCR results. These results suggest that EFIRM has potential to be a non-invasive, PCR-free, biopsy-free rapid solution for detecting mutations relating to lung cancer directly from biofluid. Streamlining of the testing process means faster results with greater affordability.